SCHEDULE: Bering Partners Discloses 9.99% Stake in CalciMedica

Bering Partners II, L.P. and related entities have filed an amendment to their Schedule 13D, disclosing a beneficial ownership of 9.99% in CalciMedica, Inc., primarily through warrants and common stock.

Summary

• Bering Partners II, L.P., along with its general partner Bering Partners II GP, L.L.C., Evgeny Zaytsev, and Philip Sawyer, have filed an amendment to their Schedule 13D for CalciMedica, Inc.
• The filing indicates a beneficial ownership of 3,553,398 shares of CalciMedica's common stock, representing 9.99% of the class.
• This ownership includes 2,113,513 shares of common stock, 130,651 shares underlying common stock warrants exercisable within 60 days, 654,617 shares underlying Series A warrants exercisable within 60 days, and 654,617 shares underlying Series B warrants exercisable within 60 days.
• The total ownership calculation is based on 35,581,345 shares outstanding as of August 5, 2026, as reported by CalciMedica in its Form 10-Q filed on August 11, 2026, plus shares underlying warrants exercisable within 60 days.
• A Beneficial Ownership Limitation prevents the exercise of certain Series A and Series B warrants if it would result in ownership exceeding 9.99%.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, primarily due to the nature of a Schedule 13D filing which indicates a significant ownership stake and potential for influence, but without explicit positive or negative operational news.

Positives

• The reporting persons have secured a significant ownership stake (9.99%) in CalciMedica, Inc., indicating confidence in the company's potential.
• The filing confirms that the necessary stockholder approval for the issuance of Series A and Series B warrants was obtained on August 19, 2026.

Negatives

• The filing is an amendment to a Schedule 13D, which typically signifies a change in ownership or intent by a significant shareholder, potentially leading to market speculation.
• The Beneficial Ownership Limitation on certain warrants restricts the ability to increase ownership beyond 9.99%, capping potential upside for these instruments.

Risks

• The primary risk is the potential for increased scrutiny or activism from a significant shareholder holding nearly 10% of the company's stock.
• Future stock price performance could be influenced by the actions or intentions of Bering Partners II, L.P. and its affiliates.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from CalciMedica, Inc. regarding its financial performance or strategic direction. The outlook is primarily shaped by the ownership stake disclosed.

Management Comments

• Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person.

Industry Context

StockSavvy.ai notes that significant ownership filings like this Schedule 13D are common in the biotechnology and pharmaceutical sectors, where substantial investment is often required for development, and investor stakes can be concentrated.

Stakeholder Impact

• Shareholders: May experience increased volatility or interest in the stock due to the significant ownership disclosure.
• Management: May face increased engagement or potential influence from Bering Partners II, L.P. regarding corporate strategy.

Next Steps

• Monitor future filings and corporate actions by CalciMedica, Inc. for any strategic shifts or operational updates.
• Observe potential future actions or communications from Bering Partners II, L.P. and its affiliates regarding their investment.

Key Dates

Recommendation

The filing indicates a significant ownership stake by Bering Partners II, L.P., but does not provide new operational or financial performance data for CalciMedica, Inc. This suggests a neutral stance, warranting a 'hold' recommendation until further information on the company's performance or the investor's intentions becomes available.

Keywords

CalciMedica, Schedule 13D, Bering Partners, Beneficial Ownership, Warrants, Common Stock, SEC Filing, Ownership Stake